Literature DB >> 30294731

FOXF2 differentially regulates expression of metabolic genes in non-cancerous and cancerous breast epithelial cells.

Pang-Kuo Lo1.   

Abstract

Forkhead box F2 (FOXF2) functions as a transcription factor and is critically involved in programming organogenesis and regulating epithelial-to-mesenchymal transition (EMT) and cell proliferation. We recently have revealed that FOXF2 can exert distinct functional effects on different molecular subtypes of breast cancer. We found that FOXF2 expression is epigenetically silenced in luminal breast cancers due to its tumor-suppressive role in DNA replication regulation. In contrast, FOXF2 is overexpressed in basal-like triple-negative breast cancers (TNBCs) due to its oncogenic role in promoting EMT. Although our and other studies have shown that FOXF2 dysregulation is critical for tumorigenesis of various tissue types, the role of FOXF2 in metabolic rewiring of cancer remains unknown. In this study, we analyzed our previous microarray data to understand the metabolic role of FOXF2 in non-cancerous and cancerous breast epithelial cells. Our studies showed that in non-cancerous breast epithelial cells FOXF2 can also play a dual role either in tumor suppression or in tumor promotion through regulating expression of tumor-suppressive and oncogenic metabolic genes. Furthermore, we found that FOXF2-regulated metabolic genes are not conserved between non-cancerous and cancerous breast epithelial cells and FOXF2 is involved in metabolic rewiring in breast cancer cells. This is the first report to explore the metabolic function of FOXF2 in breast cancer.

Entities:  

Keywords:  FOXF2; breast cancer; metabolism

Year:  2018        PMID: 30294731      PMCID: PMC6169805          DOI: 10.15761/TDM.1000103

Source DB:  PubMed          Journal:  Trends Diabetes Metab


  33 in total

1.  Decreased mRNA expression of transcription factor forkhead box F2 is an indicator of poor prognosis in patients with resected esophageal squamous cell carcinoma.

Authors:  Yu-Zhen Zheng; Jing Wen; Xun Cao; Hong Yang; Kong-Jia Luo; Qian-Wen Liu; Qing-Yuan Huang; Jun-Ying Chen; Jian-Hua Fu
Journal:  Mol Clin Oncol       Date:  2015-02-16

2.  Efficient use of exogenous isoprenols for protein isoprenylation by MDA-MB-231 cells is regulated independently of the mevalonate pathway.

Authors:  Fredrick Onono; Thangaiah Subramanian; Manjula Sunkara; Karunai Leela Subramanian; H Peter Spielmann; Andrew J Morris
Journal:  J Biol Chem       Date:  2013-08-01       Impact factor: 5.157

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

4.  Dysregulation of the mevalonate pathway promotes transformation.

Authors:  James W Clendening; Aleks Pandyra; Paul C Boutros; Samah El Ghamrasni; Fereshteh Khosravi; Grace A Trentin; Anna Martirosyan; Anne Hakem; Razqallah Hakem; Igor Jurisica; Linda Z Penn
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-09       Impact factor: 11.205

Review 5.  The Emerging Hallmarks of Cancer Metabolism.

Authors:  Natalya N Pavlova; Craig B Thompson
Journal:  Cell Metab       Date:  2016-01-12       Impact factor: 27.287

Review 6.  Prolidase-proline dehydrogenase/proline oxidase-collagen biosynthesis axis as a potential interface of apoptosis/autophagy.

Authors:  Ilona Zareba; Jerzy Palka
Journal:  Biofactors       Date:  2016-04-04       Impact factor: 6.113

7.  Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor.

Authors:  Peng-Zhou Kong; Fan Yang; Lin Li; Xiao-Qing Li; Yu-Mei Feng
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

8.  FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer.

Authors:  Qing-Shan Wang; Peng-Zhou Kong; Xiao-Qing Li; Fan Yang; Yu-Mei Feng
Journal:  Breast Cancer Res       Date:  2015-02-26       Impact factor: 6.466

9.  Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.

Authors:  Michael J Lewis; John P Wiebe; J Godfrey Heathcote
Journal:  BMC Cancer       Date:  2004-06-22       Impact factor: 4.430

10.  FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21Cip1 CDK inhibitor.

Authors:  David Milewski; Arun Pradhan; Xinjian Wang; Yuqi Cai; Tien Le; Brian Turpin; Vladimir V Kalinichenko; Tanya V Kalin
Journal:  Oncogene       Date:  2016-07-18       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.